From: Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study
Decimal Visual Acuity
Below 0.5
Above 0.6
N = 58
N = 41
Age
74.5 (±7.9)
71.3 (±10.3)
Sex
 Male
45 (77.6%)
32 (78%)
 Female
13 (22.4%)
9 (22%)
Type of AMD
 AMD
51 (87.9%)
 PCV
4 (6.9%)
 RAP
3 (5.2%)
.